Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy
Elise A. Chong, Marco Ruella, Stephen J. Schuster
Abstract
Long-Term Follow-up of CAR T-Cell–Treated Lymphoma Progression-free survival at 5 years was 31% in patients with diffuse large B-cell lymphoma and 43% in patients with follicular lymphoma. A total ...
Topics & Concepts
LymphomaFollicular lymphomaRefractory (planetary science)MedicineOncologyInternal medicineB cellCAR T-cell therapyCellB-cell lymphomaCancer researchImmunologyBiologyCancerImmunotherapyChimeric antigen receptorAntibodyGeneticsAstrobiologyCAR-T cell therapy researchViral Infectious Diseases and Gene Expression in InsectsVirus-based gene therapy research